NCT03720626Available不适用
Managed Access Programs for SEG101, Crizanlizumab
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
研究概览
简要总结
The purpose of this registration is to list Managed Access Programs (MAPs) related to SEG101, Crizanlizumab
详细描述
CSEG101A2001M - Available - Managed Access Program (MAP) Cohort Treatment Plan CSEG101A2001M to provide access to Crizanlizumab for sickle cell disease patients with history of vaso-occlusive crisis
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 12 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •An independent request was received from a licensed physician. The patient has a serious or life-threatening disease or condition and there is no comparable or satisfactory alternative therapy available for diagnosis, monitoring, or treatment.
- •The patient is not eligible or able to enrol in a clinical trial or continue participation in such trial.
- •There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.
- •The patient must meet any other medical criteria established by the medical experts responsible for the product or by the health authority in the country of request (as applicable).
- •Provision of the product will not interfere with the initiation, conduct, or completion of a Novartis clinical trial or overall development program.
- •Managed Access provision is allowed per local laws/regulations.
排除标准
- 未提供
研究者
相似试验
Unknown
不适用
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia VeraPolycythemia VeraNCT05269771Novartis Pharmaceuticals
Available
不适用
Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous UrticariaChronic Spontaneous UrticariaNCT05170724Novartis Pharmaceuticals
Unknown
不适用
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic MelanomaMelanomaNCT04489433Novartis Pharmaceuticals
Available
不适用
Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast CancerHR+, HER2-, Advanced Breast CancerNCT04473040Novartis Pharmaceuticals
Available
不适用
Managed Access Programs for BYL719, AlpelisibPIK3CA-Related Overgrowth Spectrum (PROS)Breast CancerNCT04085653Novartis Pharmaceuticals